Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: KW-2450 in combination with lapatinib and letrozole
Sponsor: Kyowa Hakko Kirin Pharma, Inc.